Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915602 | Completed Phase 2 FDA Drug

• 2 other identifiers: 167282013-000241-39
• Study Type: interventional
• Target: 14
• Locations: 21 countries
• Sites: 79

Brief Summary

This is a study to investigate the potential clinical benefit of refametinib when given in combination with sorafenib as first line treatment in patients with unresectable or metastatic HCC carrying a RAS mutation. The study will be conducted in 2 stages. Approximately 95 patients (15 at Stage 1/ 80 at Stage 2) will be accrued to this study to receive treatment. Stage 2 of the trial will only be conducted if at least 5 out of 15 patients at Stage 1 show at least partial response according to an objective criteria to evaluate tumor size based on contrast enhancement \[modified response evaluation criteria in solid tumors (mRECIST)\] assessed by external independent radiologists. Refametenib is an oral (i.e. taken by mouth) protein kinase inhibitor. A kinase inhibitor targets certain key proteins that are essential for the survival of the cancer cell. By specifically targeting these proteins, refametinib in combination with sorafenib may stop cancer growth. The growth of the tumor may be decreased by preventing these specific proteins from functioning. The primary endpoint (the most meaningful result to be tracked) of this study is based on the rate of response, i.e. the disease getting smaller. The aim is to show that the therapy with refametinib in combination with sorafenib improves the response rate in this patient population compared to historical results observed with the sorafenib only.

Conditions

Carcinoma, Hepatocellular

Keywords

Hepatocellular Carcinoma; Mitogen-activated Extracellular-signal-regulated kinase (MEK) inhibitor; Sorafenib; Objective tumor response rate (ORR); modified RECIST criteria

Outcome Measures

Primary Outcomes (1)

• Objective tumor response according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) assessed by central radiological review

  Approximately 36 months

Secondary Outcomes (11)

• Objective tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 assessed by central radiological review

  Approximately 36 months

• Objective tumor response according to RECIST 1.1 and mRECIST assessed by investigators

  Approximately 36 months

• Disease control (central and investigator's assessment)

  Approximately 36 months

• Overall survival

  Approximately 36 months

• Time to radiographic tumor progression (central and investigator's assessment)

  Approximately 36 months

Study Arms (1)

Refametinib and Sorafenib (Nexavar)

EXPERIMENTAL

In Cycle 1 reduced sorafenib dose (600 mg daily; 200 mg in the morning + 400 mg in the evening) is administered, which is escalated to the standard dose in Cycle 2, if no Hand-foot skin reaction (HFSR), fatigue, or gastrointestinal (GI) toxicities of grade 2 or higher occur. For the purposes of data recording, the treatment period will be divided into 3-week cycles. Patients will continue on treatment until at least one of the following occurs (main criteria): Progressive Disease (PD) {PD as defined by mRECIST criteria or clinical progression \[e.g. Eastern Cooperative Oncology Group performance status (ECOG PS) of ≥3\], treatment may be continued past radiological progression, provided the patient derives clinical benefit as judged by the treating physician.}, Death, Unacceptable toxicity, Subject withdraws consent, Treating physician determines discontinuation of treatment is in the subject's best interest, Substantial non-compliance with the protocol

Drug: Refametinib (BAY86-9766); Drug: Sorafenib (BAY43-9006)

Interventions

Refametinib (BAY86-9766) DRUG

Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid

Refametinib and Sorafenib (Nexavar)

Sorafenib (BAY43-9006) DRUG

Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.

Refametinib and Sorafenib (Nexavar)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eligibility criteria for RAS mutation testing
• Unresectable or metastatic HCC, confirmed either by histology or clinically according to the American Association for the Study of Liver Disease (AASLD) criteria for cirrhotic patients. For non-cirrhotic patients, histological confirmation is mandatory.
• Male or female ≥18 years of age.
• Eastern Cooperative Oncology Group (ECOG) performance state 0 or 1.
• Life expectancy of at least 12 weeks.
• No prior use of targeted agents, experimental therapy or systemic anti-cancer treatment.
• No previous treatment with sorafenib or refametinib. Criteria for study treatment eligibility
• Patient must harbor GTPase Kirsten rat sarcoma viral oncogene homolog (KRAS) or Neuroblastoma RAS viral oncogene homolog (NRAS) mutation based on Beads, emulsions, amplification, and magnetic technology, sensitive mutation detection (BEAMing) plasma test.
• Patients must have at least one uni-dimensional measurable lesion by Computed tomography (CT) or Magnetic resonance (MR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Modified Response Evaluation Criteria in Solid Tumors (mRECIST) which is either naïve (not previously treated by local therapy such as surgery, radiation therapy, hepatic arterial therapy, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) or previously treated and has progressed until baseline (both measureable lesion and/or progressed lesion have to be confirmed by central image review of baseline and progression scan).
• ECOG performance status of 0 or 1.
• Liver function status of Child-Pugh Class A.
• Adequate bone morrow, liver, and renal function
• Patient has within normal range cardiac function confirmed by the enrolling clinical institute as measured by echocardiogram or multiple gated acquisition (MUGA) scan.
• Patients who are therapeutically anti-coagulated with an agent such as warfarin or heparin are allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists. Close monitoring of at least weekly evaluations will be performed until International normalized ratio (INR) is stable (within Child Pugh class A threshold) based on a measurement at pre-dose, as defined by the local standard of care.

You may not qualify if:

• Any Cancer curatively treated \< 3 years prior to study entry, except cervical carcinoma in situ (CIS), treated basal cell carcinoma, and superficial bladder tumors \[Staging: noninvasive papillary tumor (Ta), CIS carcinoma (Tis) and tumor invades lamina propria (T1)\].
• Patients who are eligible for surgery, liver transplantation, ablation or transarterial chemoembolization for HCC.
• History of cardiac disease:
• Congestive heart failure New York Heart Association (NYHA) \> class 2.
• Unstable angina (angina symptoms at rest, new-onset angina i.e. within the last 3 months) or myocardial infarction (MI) within the past 6 months prior to start of screening.
• Cardiac arrhythmias requiring anti-arrhythmic therapy.
• QTc (corrected QT interval) \> 480 ms
• Uncontrolled hypertension (systolic blood pressure \[BP\] \>150 mmHg or diastolic blood pressure \>90 mmHg despite optimal medical management).
• Ongoing infection \> Grade 2 according to National Cancer Institute - Common Toxicity Criteria for Adverse Events version 4.03 (NCI-CTCAE version 4.03) Hepatitis B is allowed if no active replication (defined as abnormal Alanine aminotransferase \[ALT\] \>2x Upper limit normal \[ULN\] associated with Hepatitis B virus \[HBV\] DNA \>20,000 IU/mL) is present. Hepatitis C is allowed if no antiviral treatment is required.
• Known history of, or symptomatic metastatic brain or meningeal tumors (head CT or MR at Screening to confirm the absence of central nervous system \[CNS\] disease if patient had symptoms suggestive or consistent with CNS disease).
• History of interstitial lung disease (ILD).
• History of hepatic encephalopathy.
• History of organ allograft, cornea transplantation will be allowed.
• History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR).
• Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for RVO or CSR.

Sponsors & Collaborators

• Bayer: lead

Study Sites (79)

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Vienna, 1090, Austria

Location

Unknown Facility

Bruxelles - Brussel, 1070, Belgium

Location

Unknown Facility

Edegem, 2650, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Liège, 4000, Belgium

Location

Unknown Facility

Guangzhou, Guangdong, 510515, China

Location

Unknown Facility

Beijing, 100071, China

Location

Unknown Facility

Shanghai, 200032, China

Location

Unknown Facility

Hradec Králové, 500 05, Czechia

Location

Unknown Facility

Olomouc, 775 20, Czechia

Location

Unknown Facility

Bordeaux, 33000, France

Location

Unknown Facility

Caen, 14033, France

Location

Unknown Facility

Lyon, 69004, France

Location

Unknown Facility

Marseille, 13005, France

Location

Unknown Facility

Nice, 06202, France

Location

Unknown Facility

Paris, 75012, France

Location

Unknown Facility

Saint-Priest-en-Jarez, 42270, France

Location

Unknown Facility

Vandœuvre-lès-Nancy, 54511, France

Location

Unknown Facility

Heidelberg, Baden-Wurttemberg, 69120, Germany

Location

Unknown Facility

Tübingen, Baden-Wurttemberg, 72076, Germany

Location

Unknown Facility

Frankfurt am Main, Hesse, 60596, Germany

Location

Unknown Facility

Essen, North Rhine-Westphalia, 45136, Germany

Location

Unknown Facility

Essen, North Rhine-Westphalia, 45147, Germany

Location

Unknown Facility

Magdeburg, Saxony-Anhalt, 39120, Germany

Location

Unknown Facility

Berlin, 10967, Germany

Location

Unknown Facility

Hamburg, 20246, Germany

Location

Unknown Facility

Hong Kong, Hong Kong

Location

Unknown Facility

Budapest, 1062, Hungary

Location

Unknown Facility

Debrecen, 4032, Hungary

Location

Unknown Facility

Pécs, 7932, Hungary

Location

Unknown Facility

Zalaegerszeg, 8900, Hungary

Location

Unknown Facility

Haifa, 3109601, Israel

Location

Unknown Facility

Jerusalem, 9112001, Israel

Location

Unknown Facility

Petah Tikva, 4941492, Israel

Location

Unknown Facility

Tel Aviv, 64239, Israel

Location

Unknown Facility

Bologna, Emilia-Romagna, 40138, Italy

Location

Unknown Facility

Rome, Lazio, 00168, Italy

Location

Unknown Facility

Milan, Lombardy, 20122, Italy

Location

Unknown Facility

Milan, Lombardy, 20133, Italy

Location

Unknown Facility

Nagoya, Aichi-ken, 466-8560, Japan

Location

Unknown Facility

Chiba, Chiba, 260-8677, Japan

Location

Unknown Facility

Fukuoka, Fukuoka, 810-8563, Japan

Location

Unknown Facility

Yokohama, Kanagawa, 241-8515, Japan

Location

Unknown Facility

Osakasayama-shi, Osaka, 589-8511, Japan

Location

Unknown Facility

Irima-gun, Saitama, 350-0495, Japan

Location

Unknown Facility

Bunkyo-ku, Tokyo, 113-8655, Japan

Location

Unknown Facility

Itabashi-ku, Tokyo, 173-8610, Japan

Location

Unknown Facility

Kyoto, 606-8507, Japan

Location

Unknown Facility

Osaka, 534-0021, Japan

Location

Unknown Facility

Osaka, 545-8586, Japan

Location

Unknown Facility

Auckland, 1023, New Zealand

Location

Unknown Facility

Singapore, 169610, Singapore

Location

Unknown Facility

Seoul, Seoul Teugbyeolsi, 08308, South Korea

Location

Unknown Facility

Daegu, 700-721, South Korea

Location

Unknown Facility

Seoul, 03722, South Korea

Location

Unknown Facility

Seoul, 05505, South Korea

Location

Unknown Facility

Seoul, 06351, South Korea

Location

Unknown Facility

Seoul, 06591, South Korea

Location

Unknown Facility

Seoul, 110-744, South Korea

Location

Unknown Facility

Santiago de Compostela, A Coruña, 15706, Spain

Location

Unknown Facility

L'Hospitalet de Llobregat, Barcelona, 08907, Spain

Location

Unknown Facility

Vigo, Pontevedra, 36071, Spain

Location

Unknown Facility

Oviedo, Principality of Asturias, 33011, Spain

Location

Unknown Facility

Madrid, 28007, Spain

Location

Unknown Facility

Madrid, 28050, Spain

Location

Unknown Facility

Bern, 3010, Switzerland

Location

Unknown Facility

Tainan, 704, Taiwan

Location

Unknown Facility

Tainan, 736, Taiwan

Location

Unknown Facility

Taipei, 10002, Taiwan

Location

Unknown Facility

Chiang Mai, 50200, Thailand

Location

Unknown Facility

Khon Kaen, 40002, Thailand

Location

Unknown Facility

Songkhla, 90110, Thailand

Location

Unknown Facility

Istanbul, 34093, Turkey (Türkiye)

Location

Unknown Facility

Istanbul, 34349, Turkey (Türkiye)

Location

Unknown Facility

Istanbul, 34899, Turkey (Türkiye)

Location

Unknown Facility

Mersin, 33070, Turkey (Türkiye)

Location

Unknown Facility

Birmingham, B15 2TH, United Kingdom

Location

Unknown Facility

London, SE5 9RS, United Kingdom

Location

Related Links

• Click here to find results for studies related to Bayer Healthcare products.
• Click here to find information about studies related to Bayer Healthcare products conducted in Europe.

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; Sorafenib

Condition Hierarchy (Ancestors)

Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Liver Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Digestive System Diseases; Liver Diseases

Intervention Hierarchy (Ancestors)

Phenylurea Compounds; Urea; Amides; Organic Chemicals; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Niacinamide; Nicotinic Acids; Acids, Heterocyclic; Heterocyclic Compounds; Pyridines; Heterocyclic Compounds, 1-Ring

Study Officials

• Bayer Study Director

  Bayer

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 24, 2013
• First Posted: August 5, 2013
• Study Start: September 27, 2013
• Primary Completion: July 29, 2015
• Study Completion: February 8, 2017
• Last Updated: April 8, 2021

Record last verified: 2021-04

Locations

TW (3); KR (7); CZ (2); IL (4); FR (8); US (1); CN (3); TU (4); TH (3); IT (4); JP (11); CH (1); BE (4); SG (1); GB (2); DE (8); AU (1); HK (1); NZ (1); ES (6); HU (4)